Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: GRFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.19
1 Year Target Price $12.19
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.11% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.00B USD | Price to earnings Ratio 18.55 | 1Y Target Price 12.19 |
Price to earnings Ratio 18.55 | 1Y Target Price 12.19 | ||
Volume (30-day avg) 2 | Beta 1.02 | 52 Weeks Range 6.09 - 10.96 | Updated Date 10/25/2025 |
52 Weeks Range 6.09 - 10.96 | Updated Date 10/25/2025 | ||
Dividends yield (FY) 1.86% | Basic EPS (TTM) 0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4% | Operating Margin (TTM) 18.48% |
Management Effectiveness
Return on Assets (TTM) 4.43% | Return on Equity (TTM) 4.99% |
Valuation
Trailing PE 18.55 | Forward PE 11.09 | Enterprise Value 18540442891 | Price to Sales(TTM) 1.07 |
Enterprise Value 18540442891 | Price to Sales(TTM) 1.07 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA 9.77 | Shares Outstanding 258223736 | Shares Floating 535070698 |
Shares Outstanding 258223736 | Shares Floating 535070698 | ||
Percent Insiders - | Percent Institutions 58.06 |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols was founded in Barcelona, Spain in 1909. It is a global healthcare company and a leading producer of plasma-derived medicines. Over the decades, Grifols has expanded internationally through acquisitions and organic growth, solidifying its position in the plasma industry.
Core Business Areas
- Bioscience: This division researches, develops, manufactures, and commercializes plasma-derived protein therapies. Key products include immunoglobulins, albumin, alpha-1 antitrypsin, and coagulation factors.
- Diagnostic: This division develops, manufactures, and commercializes in-vitro diagnostics products. It specializes in transfusion medicine, including blood typing and screening, and also offers specialized diagnostics for other clinical areas.
- Bio Supplies: This division develops, manufactures and sells biological products for non-therapeutic uses such as in-vitro diagnostics, as well as providing a range of biological materials and related services to research institutions and manufacturers.
- Hospital: This division provides hospital pharmacy products, IV therapies, and clinical nutrition products.
Leadership and Structure
Grifols SA ADR is led by a board of directors and an executive leadership team. The structure includes various operational and functional divisions, with a global presence across numerous countries.
Top Products and Market Share
Key Offerings
- Albumin: Albumin is used to treat conditions where blood volume is low or there is a lack of protein. Grifols is a significant player in this market. Market share data is varied but estimated to be 15-20%. Competitors include CSL Behring, Takeda, and Octapharma.
- Immunglobulins (IVIG): IVIG is used to treat various immunodeficiency and autoimmune diseases. Grifols holds a significant position in the IVIG market. Market share is estimated to be 20-25%. Competitors include CSL Behring, Takeda, Octapharma, and Kedrion.
- Alpha-1 Antitrypsin (AAT): AAT is used to treat alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver disease. Grifols is a leading producer of AAT therapies. Market share is estimated to be 35-40%. Competitors include CSL Behring and Kamada.
- Factor VIII: Factor VIII used to treat Hemophilia. Competitors include Novo Nordisk, Roche and Bayer
Market Dynamics
Industry Overview
The plasma-derived therapies industry is driven by increasing demand for treatments for rare and chronic diseases. It is characterized by high barriers to entry due to regulatory requirements and the complexity of plasma fractionation.
Positioning
Grifols is a leading player in the plasma-derived therapies market, with a strong focus on innovation, quality, and global expansion. They have competitive advantages in manufacturing capacity and plasma collection networks.
Total Addressable Market (TAM)
The global plasma fractionation market is expected to reach $46.2 billion by 2028. Grifols is well-positioned to capture a significant share of this growing market.
Upturn SWOT Analysis
Strengths
- Extensive plasma collection network
- Diversified product portfolio
- Strong manufacturing capabilities
- Global presence
- Commitment to research and development
Weaknesses
- High debt levels
- Dependence on plasma supply
- Regulatory scrutiny
- Fluctuations in plasma costs
- Competition from other plasma fractionators
Opportunities
- Expanding into emerging markets
- Developing new plasma-derived therapies
- Acquiring complementary businesses
- Leveraging technology to improve efficiency
- Increasing demand for plasma-derived therapies
Threats
- Plasma supply disruptions
- Pricing pressures
- Regulatory changes
- Competition from biosimilars
- Economic downturns
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Takeda (TAK)
- Octapharma
- Kedrion
Competitive Landscape
Grifols competes with other major plasma fractionators based on product portfolio, manufacturing capacity, plasma collection network, and geographic presence. Grifols has a strong presence in the alpha-1 antitrypsin market.
Major Acquisitions
Biotest
- Year: 2022
- Acquisition Price (USD millions): 1100
- Strategic Rationale: Expanded plasma supply and manufacturing capacity in Europe.
Growth Trajectory and Initiatives
Historical Growth: Grifols has experienced significant growth over the past decade through organic expansion and acquisitions.
Future Projections: Analyst projections vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include expanding plasma collection capacity, launching new products, and investing in research and development.
Summary
Grifols is a strong player in the plasma-derived therapies market, with a diversified product portfolio and global presence. High debt levels and dependence on plasma supply are potential challenges. The company can capitalize on increasing demand for plasma-derived therapies by expanding into emerging markets and innovating new treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23833 | Website https://www.grifols.com |
Full time employees 23833 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.